Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for rare diseases worldwide. It focuses on targeting alterations in cell behaviour to address previously unmet medical needs.
Ventyx Biosciences, Inc. operates in the bioscience sector, providing services in molecular biology, protein chemistry, and bioinformatics. The company’s pipeline includes the development of selective allosteric inhibitors, such as tyrosine kinase 2 (TYK2), to address a broad range of immune-mediated diseases, including Crohn’s disease.
Keep up-to-date on the share price of VTYX by adding it to your eToro watchlist.